Fusion-Abs

First-in-Class Fusion-Abs

Fusion Antibodies

Category

Fusion
Antibody

Pipeline

IDC331

Indication

Solid Tumors

Development Stage

  • Lead optimization 5% 5%

Category

Fusion
Antibody

Pipeline

IDC332

Indication

Solid Tumors

Development Stage

  • Lead optimization 5% 5%

Improving Accessibility & Affordability for Enhancing Patient Access to Medications

Prestige Biopharma strives to enhance drug accessibility for patients’ unmet needs through the development of novel antibody therapeutics and biosimilars. Our portfolio of 12 novel antibody pipelines represents our mission and efforts to fight serious cancers like pancreatic cancer for improving patients’ lives.

Our groundbreaking accomplishments

First-in-Class

Biosimliar Pipeline